Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-10 4:44 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | Frazier Life Sciences Public Fund L.P. | 1,488,889 5% | 1,488,889 (New Position) | View |
| 2024-02-14 5:01 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | RA CAPITAL MANAGEMENT L.P. | 5,551,295 18.7% | 1,777,778 (+47.11%) | View |
| 2024-02-14 4:57 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | CITADEL ADVISORS LLC | 1,556,842 5.2% | 219,849 (+16.44%) | View |
| 2024-02-14 2:29 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | PFIZER INC PFE | 1,362,499 4.58% | 1,362,499 (New Position) | View |
| 2024-02-13 5:11 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | Easom Eric | 1,572,170 5.2% | 1,572,170 (New Position) | View |
| 2024-02-12 2:05 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | JANUS HENDERSON GROUP PLC JHG | 1,279,975 4.3% | 279,899 (+27.99%) | View |
| 2024-02-09 4:29 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | TCG Crossover GP I LLC | 2,678,209 9% | 1,388,889 (+107.72%) | View |
| 2024-02-09 07:06 am Sale | 13G | AN2 THERAPEUTICS INC ANTX | Adjuvant Global Health Technology Fund L.P. | 2,473,500 8.3% | -123,880 (-4.77%) | View |
| 2023-07-25 4:19 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | TCG Crossover GP I LLC | 1,289,320 6.6% | 1,289,320 (New Position) | View |
| 2023-07-05 4:55 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | JANUS HENDERSON GROUP PLC JHG | 1,000,076 5.1% | 1,000,076 (New Position) | View |
| 2023-02-14 4:45 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | RA CAPITAL MANAGEMENT L.P. | 3,773,517 19.5% | 106,854 (+2.91%) | View |
| 2023-02-14 11:45 am Sale | 13G | AN2 THERAPEUTICS INC ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,563,963 8.1% | -52,702 (-3.26%) | View |
| 2023-02-14 08:26 am Sale | 13G | AN2 THERAPEUTICS INC ANTX | CITADEL ADVISORS LLC | 1,336,993 6.9% | -24 (-0.00%) | View |
| 2023-02-13 5:06 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | PFIZER INC PFE | 1,362,499 7.02% | 1,362,499 (New Position) | View |
| 2023-02-13 4:45 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | Brii Biosciences Ltd | 1,048,479 5.4% | 1,048,479 (New Position) | View |
| 2023-02-10 4:57 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | Adjuvant Global Health Technology Fund L.P. | 2,597,380 13.4% | 2,597,380 (New Position) | View |
| 2022-04-08 4:31 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | RA CAPITAL MANAGEMENT L.P. | 3,666,663 19.6% | 3,666,663 (New Position) | View |
| 2022-04-08 4:11 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | CITADEL ADVISORS LLC | 1,337,017 7.1% | 1,337,017 (New Position) | View |
| 2022-04-04 4:38 pm Purchase | 13G | AN2 THERAPEUTICS INC ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,616,665 8.6% | 1,616,665 (New Position) | View |